Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin after kidney transplantation in type 2 diabetes with proteinuria
ChiCTR2200063658Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of canagliflozin in type 2 diabetes mellitus (T2DM) and proteinuria (2 arms), sponsored by Renji Hospital. Primary endpoints: Serum creatinine, Blood glucose and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)proteinuria
Beyond the preview
Go deeper on ChiCTR2200063658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063658.